Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

T2 Biosystems CS (TTOO)

T2 Biosystems CS (TTOO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

T2 Biosystems CS 101 HARTWELL AVENUE LEXINGTON MA 02421 USA

www.t2biosystems.com Employees: 113 P: 781-761-4646 F: 781-357-3080

Description:

T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 7,365
Enterprise Value, $K -8,325
Shares Outstanding, K 21,043
Annual Sales, $ 7,190 K
Annual Net Income, $ -50,080 K
Last Quarter Sales, $ 1,990 K
Last Quarter Net Income, $ -10,120 K
EBIT, $ -41,660 K
EBITDA, $ -40,800 K
60-Month Beta 0.35
% of Insider Shareholders 0.05%
% of Institutional Shareholders 23.18%
Float, K 21,032
% Float 99.95%
Short Volume Ratio 0.42

Growth:

1-Year Return -93.12%
3-Year Return -99.99%
5-Year Return -99.99%
5-Year Revenue Growth -31.52%
5-Year Earnings Growth 99.70%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.57 on 11/14/24
Next Earnings Date N/A
Earnings Per Share ttm -3.89
EPS Growth vs. Prev Qtr 13.64%
EPS Growth vs. Prev Year 83.48%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-100 on 10/13/23

TTOO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -174.06%
Profit Margin % -696.52%
Debt/Equity 0.00
Price/Sales 1.02
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.67
Interest Coverage -8.38
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar